C-peptide vs DADLE
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and DADLE ([D-Ala2, D-Leu5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | DADLE |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Connecting peptide (C-peptide) | [D-Ala2, D-Leu5]-enkephalin |
| Molecular Weight | 3020.3 Da | 569.67 Da |
| Half-Life | ~20-30 min | 5-20 minutes in plasma |
| Amino Acids | 31 | 5 |
| Typical Dose | no approved analgesic dose|research-only | 0.01-2 ug per animal |
| Route | IV|subQ | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 450 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
DADLE Benefits
- ✓delta-opioid agonism
- ✓enhanced peptide stability
- ✓spinal analgesia models
- ✓research on tolerance mechanisms
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
DADLE Dosing
Intrathecal 0.01-2 ug per animal|Intracerebroventricular 0.01-1 ug per animal|In vitro 0.1-50 nM
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
DADLE Side Effects
- ⚠sedation
- ⚠motor suppression at higher doses
- ⚠opioid tolerance with repeated exposure
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
DADLE
DADLE has been studied for analgesic, neuroprotective, and receptor-selective opioid effects in animal and tissue models. It remains important as a mechanistic probe because it is more stable than endogenous enkephalins but still peptide-like in its delivery constraints.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.